drugset / Trial / NCT00070837
MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to determine the highest dose of MLN2704 that can be given multiple times safely to patients with prostate cancer, and to identify any side effects associated with taking the drug. This study will also evaluate how MLN2704 is taken up, broken down and eliminated by the body.
Timeline
- Start
- 2003-10
- Primary completion
- —
- Completion
- 2004-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MLN2704 | Monoclonal antibody | — | — |